Cantor Fitzgerald Sticks to Their Buy Rating for CymaBay Therapeutics (CBAY)

Cantor Fitzgerald analyst Eliana Merle maintained a Buy rating on CymaBay Therapeutics (CBAY) today and set a price target of $20. The company’s shares opened today at $9.49.

According to, Merle is a 1-star analyst with an average return of -5.5% and a 23.5% success rate. Merle covers the Healthcare sector, focusing on stocks such as Aerpio Pharmaceuticals Inc, AnaptysBio Inc, and Galapagos NV.

Currently, the analyst consensus on CymaBay Therapeutics is a Strong Buy with an average price target of $17.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $15.59 and a one-year low of $6.31. Currently, CymaBay Therapeutics has an average volume of 572.7K.

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Carl Goldfischer, a Director at CBAY sold 11,675 shares for a total of $105,309.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of biopharmaceutical products. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid.